Although the relationships among immune suppression, the inflammatory response, and lung damage in COVID-19 remain to be unraveled, the link between elevated inflammatory markers and respiratory failure has led to the use of immunosuppressive agents ranging from corticosteroids to inhibitors of cytokines, such as interleukin-6 (IL-6) and other inflammatory mediators (19). This evidence concerns the gene IL6 and respiratory failure.